Shares in biotech company Recursion Pharmaceuticals ( RXRX 12.07%) surged by more than 12% by 11 a.m. ET today. The move is ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027.

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $5.72, moving +2.24% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 0.28%.

Objective Long-term azithromycin treatment effectively prevents acute exacerbations of chronic obstructive pulmonary disease (COPD). However, patients would benefit from better identification of ...